MCID: ADN027
MIFTS: 61

Adenomyosis

Categories: Muscle diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Adenomyosis

MalaCards integrated aliases for Adenomyosis:

Name: Adenomyosis 58 12 77 54 45 15 17
Endometriosis of Uterus 12 15 74
Endometriosis of Myometrium 12
Endometriosis, Myometrium 12
Endometriosis Interna 12
Uterine Adenomyosis 12

Characteristics:

OMIM:

58
Inheritance:
autosomal vs. x-linked dominant



Classifications:



External Ids:

Disease Ontology 12 DOID:288
OMIM 58 600458
ICD9CM 36 617.0
MeSH 45 D062788
NCIt 51 C6996
SNOMED-CT 69 76376003
ICD10 34 N80.0
MedGen 43 C0341858
UMLS 74 C0341858

Summaries for Adenomyosis

NIH Rare Diseases : 54 Adenomyosis is a condition that affects the uterus. In women with adenomyosis, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. Some women may have no signs or symptoms of the condition. When present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. Some women may also develop an adenomyoma, which is a mass or growth within the uterus. The underlying cause of the condition is currently unknown. In general, treatment is based on the signs and symptoms present in each person. Forms of birth control that contain progesterone (such as birth control pills or an IUD) may decrease heavy bleeding while certain medications can be used to manage pain. In severe cases, a hysterectomy may be recommended.

MalaCards based summary : Adenomyosis, also known as endometriosis of uterus, is related to uterine anomalies and endometrial adenocarcinoma. An important gene associated with Adenomyosis is PGR (Progesterone Receptor), and among its related pathways/superpathways are GPCR Pathway and Nanog in Mammalian ESC Pluripotency. The drugs Estradiol and Polyestradiol phosphate have been mentioned in the context of this disorder. Affiliated tissues include uterus, breast and pituitary, and related phenotypes are abnormal bleeding and dysmenorrhea

Disease Ontology : 12 A uterine disease that is characterized by the presence of endometrial tissue grows outside of the endometrium, such as into the myometrium.

OMIM : 58 Adenomyosis is characterized by the presence of endometrial glands and stroma within the myometrium. Abnormal uterine bleeding and dysmenorrhea are the most characteristic symptoms, occurring in approximately 65% of cases (Arnold et al., 1995). (600458)

Wikipedia : 77 Adenomyosis is a gynecologic medical condition characterized by the abnormal presence of endometrial... more...

Related Diseases for Adenomyosis

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 220, show less)
# Related Disease Score Top Affiliating Genes
1 uterine anomalies 31.5 CDH1 CYP19A1 ESR1 PGR VEGFA
2 endometrial adenocarcinoma 30.6 ESR1 HOXA10 PGR VEGFA
3 endometriosis 30.3 CYP19A1 ESR1 GNRH1 HOXA10 PGR PTGS2
4 adenosarcoma 30.2 ESR1 MME PGR
5 myoma 30.1 CYP19A1 ESR1 GNRH1 HOXA10 PGR
6 endometriosis of ovary 30.0 CYP19A1 ESR1 HOXA10 PGR
7 leiomyoma 30.0 CYP19A1 ESR1 GNRH1 MME PGR
8 endometrial stromal sarcoma 29.9 CYP19A1 ESR1 MME PGR
9 leiomyomatosis 29.9 ESR1 GNRH1 PGR
10 intravenous leiomyomatosis 29.9 ESR1 MME
11 breast fibroadenoma 29.4 CYP19A1 ESR1 MME PGR
12 endometrial cancer 28.2 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MME
13 breast cancer 28.0 CDH1 CYP19A1 ESR1 GNRH1 MMP2 MMP9
14 adenocarcinoma 10.6
15 parotitis 10.5 MMP2 MMP9
16 light chain deposition disease 10.5 MMP2 MMP9
17 female reproductive endometrioid cancer 10.5 ESR1 PGR
18 intramuscular hemangioma 10.5 ESR1 PGR
19 glycogen-rich clear cell breast carcinoma 10.5 ESR1 PGR
20 vestibular gland benign neoplasm 10.5 ESR1 PGR
21 bartholin's gland adenoma 10.5 ESR1 PGR
22 vulvar syringoma 10.5 ESR1 PGR
23 lung leiomyoma 10.5 ESR1 PGR
24 extracranial arteriovenous malformation 10.5 MMP2 MMP9
25 glassy cell carcinoma of the cervix 10.4 ESR1 PGR
26 focal myositis 10.4 MMP2 MMP9
27 vulvar benign neoplasm 10.4 ESR1 PGR
28 trigonitis 10.4 ESR1 PGR
29 vulvar leiomyoma 10.4 ESR1 PGR
30 villous adenocarcinoma 10.4 MMP2 MMP9
31 balanitis xerotica obliterans 10.4 PTGS2 VEGFA
32 spastic entropion 10.4 MMP2 MMP9
33 infertility 10.4
34 lentigo maligna melanoma 10.4 MMP2 MMP9
35 predominantly cortical thymoma 10.4 ESR1 PGR
36 breast medullary carcinoma 10.4 ESR1 PGR
37 angiokeratoma circumscriptum 10.4 MMP9 VEGFA
38 breast scirrhous carcinoma 10.4 ESR1 PGR
39 bartholin's gland benign neoplasm 10.4 ESR1 PGR
40 oncocytic breast carcinoma 10.4 ESR1 PGR
41 intracystic papillary adenoma 10.4 PGR PRL
42 acute transverse myelitis 10.4 MMP2 MMP9
43 senile ectropion 10.4 MMP2 MMP9
44 progesterone resistance 10.4 ESR1 PGR
45 endometrial squamous cell carcinoma 10.4 ESR1 PGR
46 cribriform carcinoma 10.4 ESR1 PGR
47 gingival hypertrophy 10.4 MMP9 TIMP2
48 endometrial mucinous adenocarcinoma 10.4 ESR1 PGR
49 adenoid basal cell carcinoma 10.4 ESR1 PGR
50 ischemic colitis 10.3 MMP2 MMP9 VEGFA
51 apocrine adenocarcinoma 10.3 ESR1 PGR
52 odontogenic myxoma 10.3 MMP2 MMP9 VEGFA
53 serous cystadenocarcinoma 10.3 MMP2 PGR VEGFA
54 internal hemorrhoid 10.3 MMP2 MMP9
55 fallopian tube carcinoma 10.3 ESR1 PGR VEGFA
56 microcystic meningioma 10.3 MMP2 TIMP2 VEGFA
57 breast carcinoma in situ 10.3 ESR1 PGR VEGFA
58 fibrosarcoma 10.3 MMP2 MMP9 TIMP2
59 peritoneal benign neoplasm 10.3 ESR1 PGR
60 grade iii astrocytoma 10.3 MMP2 MMP9 VEGFA
61 extrapelvic endometriosis 10.3
62 pancreatic serous cystadenoma 10.3 PGR VEGFA
63 lymphangioleiomyomatosis 10.3 ESR1 MMP2 PGR
64 nasal cavity squamous cell carcinoma 10.3 MMP2 MMP9 TIMP2
65 deep angioma 10.3 ESR1 PGR
66 adenomyoma 10.3
67 aortic aneurysm, familial abdominal, 1 10.3 MMP2 MMP9 TIMP2
68 conjunctival nevus 10.3 MMP2 MMP9 NGF
69 diffuse peritoneal leiomyomatosis 10.3 ESR1 PGR
70 corneal ulcer 10.3 MMP2 MMP9 NGF
71 inguinal hernia 10.3 MMP2 MMP9 TIMP2
72 sella turcica neoplasm 10.3 PGR PRL
73 benign metastasizing leiomyoma 10.3 CYP19A1 PGR
74 adhesions of uterus 10.3 ESR1 HOXA10
75 synchronous bilateral breast carcinoma 10.3 ESR1 PGR
76 sarcoma 10.3
77 postpartum depression 10.3 ESR1 OXTR PRL
78 microvascular complications of diabetes 1 10.3 MMP9 TIMP2 VEGFA
79 progesterone-receptor positive breast cancer 10.2 CYP19A1 ESR1 PGR
80 gender identity disorder 10.2 CYP19A1 ESR1 PGR
81 prolactin producing pituitary tumor 10.2 NGF PRL
82 breast adenocarcinoma 10.2 ESR1 MMP2 MMP9
83 cervical adenocarcinoma 10.2 ESR1 PGR PTGS2
84 pelvic varices 10.2 GNRH1 PRL
85 prostatic hypertrophy 10.2 CYP19A1 ESR1 PGR
86 sick building syndrome 10.2 MMP9 VEGFA
87 periodontal disease 10.2 MMP2 MMP9 TIMP2
88 estrogen-receptor positive breast cancer 10.2 CYP19A1 ESR1 PGR
89 tuberculum sellae meningioma 10.2 PGR PRL
90 thrombosis 10.2
91 ovarian cancer 1 10.2 CDH1 MMP2 VEGFA
92 varicose veins 10.2 MMP2 MMP9 TIMP2 VEGFA
93 inflammatory breast carcinoma 10.2 CDH1 ESR1 PGR
94 pituitary infarct 10.2 GNRH1 PRL
95 lipid-rich carcinoma 10.2 CDH1 ESR1 PGR
96 cystic nephroma 10.2 MME PGR
97 laryngeal disease 10.2 CDH1 MMP2 MMP9
98 chiasmal syndrome 10.2 GNRH1 PRL
99 adamantinous craniopharyngioma 10.2 MMP9 VEGFA
100 tubular adenocarcinoma 10.2 CDH1 ESR1 PGR
101 pre-malignant neoplasm 10.2 CDH1 ESR1 PGR
102 in situ carcinoma 10.2 CDH1 ESR1 PGR
103 endometrial disease 10.2 CYP19A1 ESR1 PTGS2
104 nasopharyngeal disease 10.2 CDH1 MMP9 VEGFA
105 pharynx cancer 10.2 CDH1 MMP9 VEGFA
106 tongue cancer 10.1 CDH1 MMP2 MMP9
107 leiomyoma, uterine 10.1
108 endometrial hyperplasia 10.1
109 disseminated intravascular coagulation 10.1
110 hypogonadotropism 10.1 GNRH1 PRL
111 breast ductal carcinoma 10.1 CDH1 ESR1 PGR
112 hypothalamic disease 10.1 GNRH1 PRL
113 nervous system disease 10.1 MMP9 NGF VEGFA
114 tongue squamous cell carcinoma 10.1 CDH1 MMP2 MMP9
115 juvenile nasopharyngeal angiofibroma 10.1 CYP19A1 ESR1 PGR VEGFA
116 respiratory system disease 10.1 CDH1 MMP9 VEGFA
117 breast myofibroblastoma 10.1 ESR1 MME
118 uterine benign neoplasm 10.1 ESR1 GNRH1 PGR
119 breast adenoid cystic carcinoma 10.1 ESR1 PGR
120 oral submucous fibrosis 10.1 CDH1 MMP2 PTGS2
121 pituitary apoplexy 10.1 GNRH1 PRL
122 gallbladder cancer 10.1 CDH1 PTGS2 TIMP2
123 myxoid leiomyosarcoma 10.1 MME PGR
124 colorectal adenocarcinoma 10.1 CDH1 PTGS2 VEGFA
125 hyperprolactinemia 10.1
126 ectopic pregnancy 10.1
127 endocarditis 10.1
128 bladder disease 10.1 CDH1 MMP9 NGF
129 premenstrual tension 10.1 GNRH1 PGR PRL
130 estrogen excess 10.1 CYP19A1 ESR1 PGR PRL
131 mammographic density 10.1 CYP19A1 ESR1 PGR PRL
132 intestinal disease 10.1 CDH1 PTGS2 VEGFA
133 hypothyroidism, central, and testicular enlargement 10.1 CYP19A1 HOXA10 PRL
134 gynecomastia 10.1 CYP19A1 ESR1 PGR PRL
135 respiratory system cancer 10.0 CDH1 MMP2 MMP9 VEGFA
136 benign breast phyllodes tumor 10.0 MME PGR
137 meningioma, familial 10.0 CDH1 ESR1 PGR VEGFA
138 aromatase deficiency 10.0 CYP19A1 ESR1 GNRH1
139 psammomatous meningioma 10.0 MME MMP2 MMP9
140 ovarian hyperstimulation syndrome 10.0 CYP19A1 GNRH1 VEGFA
141 cervical carcinosarcoma 10.0 ESR1 MME PGR
142 breast benign neoplasm 10.0 ESR1 MME PGR
143 thoracic benign neoplasm 10.0 ESR1 MME PGR
144 squamous cell carcinoma 10.0 CDH1 MMP2 PTGS2 VEGFA
145 smooth muscle tumor 10.0 ESR1 MME PGR
146 pneumothorax 10.0 GNRH1 MMP2 MMP9 PGR
147 mayer-rokitansky-kuster-hauser syndrome 10.0
148 stroke, ischemic 10.0
149 leukemia 10.0
150 pre-eclampsia 10.0
151 clear cell adenocarcinoma 10.0
152 fibromatosis 10.0
153 posttransplant acute limbic encephalitis 10.0
154 male reproductive system disease 10.0 CDH1 GNRH1 VEGFA
155 colonic disease 10.0 CDH1 ESR1 PTGS2 VEGFA
156 oral cancer 10.0 CDH1 MMP2 MMP9 PTGS2
157 stomach disease 10.0 CDH1 MMP9 PTGS2 VEGFA
158 anovulation 10.0 CYP19A1 GNRH1 PRL
159 hyperandrogenism 10.0 CYP19A1 GNRH1 PRL
160 pancreas adenocarcinoma 9.9 CDH1 MMP9 PTGS2 VEGFA
161 fungal keratitis 9.9 MMP9 TIMP2
162 empty sella syndrome 9.9 GNRH1 PRL
163 malignant ovarian surface epithelial-stromal neoplasm 9.9 CDH1 ESR1 MMP2 PGR VEGFA
164 ovary epithelial cancer 9.9 CDH1 ESR1 MMP2 PGR VEGFA
165 breast disease 9.9 CYP19A1 ESR1 PGR PRL VEGFA
166 premature ovarian failure 1 9.9 CYP19A1 GNRH1 PRL
167 extrahepatic bile duct adenocarcinoma 9.9 CDH1 MME
168 endometrial stromal nodule 9.9 CYP19A1 MME PGR
169 reproductive organ benign neoplasm 9.9 CYP19A1 ESR1 GNRH1 PGR
170 uterine sarcoma 9.9 CYP19A1 ESR1 MME
171 polycystic ovary syndrome 9.9 CYP19A1 GNRH1 PRL
172 cryptorchidism, unilateral or bilateral 9.9 CYP19A1 GNRH1 HOXA10
173 gastrointestinal system cancer 9.8 CDH1 MMP2 MMP9 PTGS2 VEGFA
174 gastrointestinal system disease 9.8 CDH1 MMP2 MMP9 PTGS2 VEGFA
175 tetralogy of fallot 9.8
176 renal hypodysplasia/aplasia 1 9.8
177 insulin-like growth factor i 9.8
178 homocysteinemia 9.8
179 cervical cancer 9.8
180 thrombocytopenia 9.8
181 lymphoma 9.8
182 marantic endocarditis 9.8
183 pain agnosia 9.8
184 cardiac arrest 9.8
185 endosalpingiosis 9.8
186 cystitis 9.8
187 chronic cystitis 9.8
188 leiomyosarcoma 9.8
189 mesenchymoma 9.8
190 vaginal discharge 9.8
191 carcinosarcoma 9.8
192 ovarian cyst 9.8
193 ureteral obstruction 9.8
194 endometrioid ovary carcinoma 9.8
195 adenosarcoma of the uterus 9.8
196 cervical intraepithelial neoplasia 9.8
197 cytokine deficiency 9.8
198 desmoplastic infantile ganglioglioma 9.8
199 xp22.3 microdeletion syndrome 9.8
200 hypoxia 9.8
201 large intestine cancer 9.8 CDH1 MMP2 MMP9 PTGS2 VEGFA
202 male reproductive organ cancer 9.8 CDH1 GNRH1 MMP9 VEGFA
203 lung cancer susceptibility 3 9.8 CDH1 MMP2 MMP9 PTGS2 VEGFA
204 esophageal cancer 9.8 CDH1 MMP2 MMP9 PTGS2 VEGFA
205 ewing sarcoma 9.8 CDH1 MMP2 MMP9 PTGS2 VEGFA
206 ductal carcinoma in situ 9.7 CDH1 CYP19A1 ESR1 PGR PTGS2
207 gonadal disease 9.7 CYP19A1 ESR1 GNRH1 PRL VEGFA
208 endocrine gland cancer 9.7 CDH1 CYP19A1 ESR1 MMP2 MMP9 VEGFA
209 squamous cell carcinoma, head and neck 9.7 CDH1 MMP2 MMP9 PTGS2 TIMP2 VEGFA
210 gastric adenocarcinoma 9.7 CDH1 MMP2 MMP9 PTGS2 TIMP2 VEGFA
211 uterine carcinosarcoma 9.6 CDH1 MME PGR PTGS2
212 cholangiocarcinoma 9.6 CDH1 MME MMP9 PTGS2
213 renal cell carcinoma, nonpapillary 9.6 CDH1 MME MMP2 MMP9 VEGFA
214 myocardial infarction 9.5 ESR1 MME MMP2 MMP9 PTGS2 VEGFA
215 adamantinoma of long bones 9.4 CDH1 ESR1 MMP2 MMP9 PGR PTGS2
216 ovarian disease 9.4 CYP19A1 ESR1 GNRH1 NGF PGR PRL
217 ovarian cancer 9.2 CDH1 ESR1 GNRH1 MMP2 MMP9 PGR
218 prostate cancer 9.1 CDH1 CYP19A1 ESR1 GNRH1 MMP2 MMP9
219 female reproductive system disease 9.0 CDH1 CYP19A1 ESR1 GNRH1 MMP2 MMP9
220 reproductive system disease 8.8 CDH1 CYP19A1 ESR1 GNRH1 MMP2 MMP9

Graphical network of the top 20 diseases related to Adenomyosis:



Diseases related to Adenomyosis

Symptoms & Phenotypes for Adenomyosis

Human phenotypes related to Adenomyosis:

33 (showing 3, show less)
# Description HPO Frequency HPO Source Accession
1 abnormal bleeding 33 HP:0001892
2 dysmenorrhea 33 HP:0100607
3 abnormality of the genitourinary system 33 HP:0000119

Symptoms via clinical synopsis from OMIM:

58
Lab:
dysmenorrhea
endometrial glands and stroma within the myometrium
abnormal uterine bleeding

G U:
adenomyosis

Clinical features from OMIM:

600458

MGI Mouse Phenotypes related to Adenomyosis:

47 (showing 17, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 CDH1 CYP19A1 ESR1 GNRH1 MME MMP2
2 behavior/neurological MP:0005386 10.27 CYP19A1 ESR1 MMP9 NGF OXTR PGR
3 cardiovascular system MP:0005385 10.26 CDH1 CYP19A1 ESR1 MMP2 MMP9 NGF
4 growth/size/body region MP:0005378 10.26 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP2
5 immune system MP:0005387 10.26 CDH1 CYP19A1 ESR1 GNRH1 MME MMP2
6 endocrine/exocrine gland MP:0005379 10.24 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 OXTR
7 integument MP:0010771 10.23 CDH1 CYP19A1 ESR1 GNRH1 MME MMP9
8 hematopoietic system MP:0005397 10.16 CYP19A1 ESR1 GNRH1 MMP2 MMP9 PGR
9 digestive/alimentary MP:0005381 10.15 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP9
10 nervous system MP:0003631 10.1 CYP19A1 ESR1 GNRH1 HOXA10 MMP2 MMP9
11 muscle MP:0005369 10.06 CYP19A1 ESR1 MMP2 MMP9 NGF OXTR
12 neoplasm MP:0002006 10.02 CDH1 ESR1 GNRH1 MMP2 MMP9 PGR
13 liver/biliary system MP:0005370 9.98 CYP19A1 ESR1 GNRH1 MME PRL PTGS2
14 normal MP:0002873 9.9 CDH1 CYP19A1 ESR1 GNRH1 MMP2 NGF
15 no phenotypic analysis MP:0003012 9.8 CDH1 ESR1 NGF OXTR PGR PTGS2
16 reproductive system MP:0005389 9.7 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP9
17 skeleton MP:0005390 9.28 CYP19A1 ESR1 GNRH1 HOXA10 MMP2 MMP9

Drugs & Therapeutics for Adenomyosis

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 112, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Early Phase 1,Not Applicable 50-28-2 5757
2
Polyestradiol phosphate Approved Phase 4,Phase 3,Early Phase 1,Not Applicable 28014-46-2
3
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Ibuprofen Approved Phase 4 15687-27-1 3672
6
Dienogest Approved Phase 4,Not Applicable 65928-58-7
7
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3 57-83-0 5994
8
Nandrolone decanoate Approved, Illicit Phase 4,Not Applicable 360-70-3 9677
9
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4,Not Applicable 62-90-8 229455
10
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
11
Norethindrone Approved Phase 4 68-22-4 6230
12
Buserelin Approved, Investigational Phase 4 57982-77-1
13
Nandrolone Experimental, Investigational Phase 4,Not Applicable 434-22-0 9904
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Estradiol 3-benzoate Phase 4,Phase 3,Early Phase 1,Not Applicable
16 Estrogens Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
17 Estradiol 17 beta-cypionate Phase 4,Phase 3,Early Phase 1,Not Applicable
18 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
20 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
21 Contraceptives, Oral, Combined Phase 4,Phase 2,Early Phase 1,Not Applicable
22 Contraceptive Agents Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
23 Contraceptives, Oral Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
24 Ulipristal acetate Phase 4,Phase 2 126784-99-4
25 Anti-Inflammatory Agents Phase 4,Not Applicable
26 Cyclooxygenase Inhibitors Phase 4
27 Analgesics Phase 4,Phase 3
28 Analgesics, Non-Narcotic Phase 4
29 Anti-Inflammatory Agents, Non-Steroidal Phase 4
30 Antirheumatic Agents Phase 4
31 Antipyretics Phase 4
32 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
33 Contraceptive Agents, Male Phase 4,Not Applicable
34 Anabolic Agents Phase 4,Not Applicable
35 Androgens Phase 4,Not Applicable
36 Oxytocics Phase 4
37 Triptorelin Pamoate Phase 4,Phase 3
38 Norethindrone Acetate Phase 4
39
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
40
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
41
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
42 Ramosetron Investigational Phase 3 132036-88-5
43
Lactitol Investigational Phase 2, Phase 3 585-88-6, 585-86-4 493591
44 Deslorelin Investigational, Vet_approved Phase 3,Not Applicable 57773-65-6
45 Trace Elements Phase 3
46 Micronutrients Phase 3
47 Nutrients Phase 3
48 Antiemetics Phase 3,Not Applicable
49 Serotonin Antagonists Phase 3
50 Neurotransmitter Agents Phase 3,Phase 2,Phase 1,Not Applicable
51 Gastrointestinal Agents Phase 3,Not Applicable
52 Autonomic Agents Phase 3,Not Applicable
53 Serotonin Agents Phase 3
54 Estrogen Receptor Antagonists Phase 2, Phase 3
55 Steroid Synthesis Inhibitors Phase 2, Phase 3
56 Aromatase Inhibitors Phase 2, Phase 3
57 Estrogen Antagonists Phase 2, Phase 3
58 Luteolytic Agents Phase 2, Phase 3,Phase 3
59 Contraceptives, Postcoital Phase 2, Phase 3
60 Prolactin Release-Inhibiting Factors Phase 3
61
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
62
Levonorgestrel Approved, Investigational Phase 2,Early Phase 1,Not Applicable 797-63-7, 17489-40-6 13109
63
Ropivacaine Approved Phase 2 84057-95-4 175805 71273
64
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
65
Dopamine Approved Phase 2,Phase 1 62-31-7, 51-61-6 681
66
Quinagolide Approved, Investigational Phase 2 87056-78-8, 97805-50-0 105105
67 Diuretics, Potassium Sparing Phase 2,Early Phase 1
68 Anesthetics Phase 2,Not Applicable
69 Anti-Arrhythmia Agents Phase 2
70 Anesthetics, Local Phase 2,Not Applicable
71 Central Nervous System Depressants Phase 2,Not Applicable
72 Sodium Channel Blockers Phase 2
73 Dopamine Agents Phase 2,Phase 1
74 Dopamine agonists Phase 2,Phase 1
75
Bromocriptine Approved, Investigational Phase 1 25614-03-3 31101
76 Antiparkinson Agents Phase 1
77
Ethinyl Estradiol Approved Early Phase 1,Not Applicable 57-63-6 5991
78
Drospirenone Approved Early Phase 1 67392-87-4 68873
79
Dexamethasone acetate Approved, Investigational, Vet_approved Not Applicable 1177-87-3
80
Dexamethasone Approved, Investigational, Vet_approved Not Applicable 50-02-2 5743
81
Iodine Approved, Investigational Not Applicable,Early Phase 1 7553-56-2 807
82
Povidone Approved Not Applicable 9003-39-8
83
Povidone-iodine Approved Not Applicable 25655-41-8
84
Epinephrine Approved, Vet_approved Not Applicable 51-43-4 5816
85
Racepinephrine Approved Not Applicable 329-65-7 838
86
Bupivacaine Approved, Investigational Not Applicable 38396-39-3, 2180-92-9 2474
87
Gestodene Investigational Not Applicable 60282-87-3 3033968
88 Mineralocorticoids Early Phase 1
89 Progestins Early Phase 1,Not Applicable
90 Natriuretic Agents Early Phase 1
91 Drospirenone and ethinyl estradiol combination Early Phase 1
92 diuretics Early Phase 1
93
Ethylene Early Phase 1 74-85-1 6325
94 Mineralocorticoid Receptor Antagonists Early Phase 1
95 BB 1101 Not Applicable
96 HIV Protease Inhibitors Not Applicable
97 glucocorticoids Not Applicable
98
protease inhibitors Not Applicable
99 cadexomer iodine Not Applicable
100 Femovan Not Applicable
101 Adrenergic beta-Agonists Not Applicable
102 Adrenergic alpha-Agonists Not Applicable
103 Adrenergic Agonists Not Applicable
104 Epinephryl borate Not Applicable
105 Respiratory System Agents Not Applicable
106 Anti-Asthmatic Agents Not Applicable
107 Vasoconstrictor Agents Not Applicable
108 Bronchodilator Agents Not Applicable
109 Sympathomimetics Not Applicable
110 Mydriatics Not Applicable
111 Adrenergic Agents Not Applicable
112 Pharmaceutical Solutions Early Phase 1

Interventional clinical trials:

(showing 70, show less)
# Name Status NCT ID Phase Drugs
1 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
2 Oxytocin in MRI-HIFU Enrolling by invitation NCT03937401 Phase 4 Oxytocin
3 Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. Not yet recruiting NCT03946722 Phase 4 GnRH analogue downregulation
4 Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Not yet recruiting NCT03654144 Phase 4 Dienogest;Combined Oral Contraceptive
5 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
6 Efficacy of Trace Elements in the Treatment of Endometriosis: a Pilot Study Unknown status NCT02437175 Phase 3
7 Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy Unknown status NCT01483417 Phase 3
8 The Use of Doppler to Diagnose Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
9 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
10 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
11 Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
12 Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
13 Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Recruiting NCT03520439 Phase 2, Phase 3 Mifepristone;Placebo
14 Elastic Abdominal Binder After Open Abdominal Surgery for Benign Gynecologic Conditions Recruiting NCT03820115 Phase 3
15 Impact of Ultra-long Versus Long Down-regulation Protocol on IVF/ICSI in Adenomyosis Not yet recruiting NCT03940807 Phase 3 11.25mg GnRH agonist;0.1 mg GnRH agonist;25 µg transdermal oestradiol
16 Adenomyosis and Ulipristal Acetate Unknown status NCT02587000 Phase 2 Ulipristal acetate;Placebo
17 LNG-IUS for Treatment of Dysmenorrhea Completed NCT01601366 Phase 2 Combined oral contraceptives
18 Tactile Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding Completed NCT02248194 Phase 2
19 Superior Hypogastric Nerve Block for Pain Control Post-UFE Completed NCT02270255 Phase 2 0.75% Ropivacaine;1% Xylocaine
20 Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis Not yet recruiting NCT03749109 Phase 2 Quinagolide 1080 µg;Placebo
21 Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis Withdrawn NCT02794467 Phase 2 Epelsiban;Placebo
22 Vaginal Bromocriptine for Treatment of Adenomyosis Completed NCT01821001 Phase 1 Vaginal Bromocriptine
23 Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Unknown status NCT03037944 Early Phase 1 Yasmin
24 Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis Unknown status NCT01259180 Not Applicable
25 Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis Unknown status NCT00172588
26 Proliferation of Endometrial Stromal Cells in Adenomyosis Unknown status NCT00173212
27 Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Unknown status NCT02556411 Not Applicable LNG-IUS 13,5 mg Levonorgestrel;Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
28 Health-Related QoL Among Women Receiving Hysterectomy in NTUH Unknown status NCT00155870
29 Progestin Treatment for Endometrial Stromal Cells in Adenomyosis Unknown status NCT00155051
30 To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602 Not Applicable
31 Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Unknown status NCT02086344 Not Applicable
32 Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis Unknown status NCT03006406 Not Applicable Long term GnRH-a (3.75mg)
33 The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone (AMH) Unknown status NCT00928044
34 Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy Unknown status NCT01289314 Not Applicable
35 Histopathological Diagnosis of Adenomyosis Completed NCT02340533 Not Applicable
36 Norwegian Adenomyosis Study I Completed NCT02201719
37 Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis Completed NCT03027648 Not Applicable
38 Levonorgestrel Intrauterine System and Adenomyosis Completed NCT03104309 Not Applicable
39 Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis Completed NCT03778359 Leuprorelin;Dienogest;Progestins
40 New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma Completed NCT02997787
41 What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Completed NCT01992718 Early Phase 1
42 Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis Completed NCT03586063
43 Use of Dexamethasone in Uterine Artery Embolization Completed NCT02056717 Not Applicable Dexamethasone;Normal saline
44 Uterine Artery Embolization for Symptomatic Fibroids Completed NCT00354471
45 Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Completed NCT02192606 Not Applicable
46 Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy Completed NCT01806012 Not Applicable
47 AMH Levels Change During Treatment With GnRh Agonist Completed NCT02086279 Not Applicable GnRH analogue
48 Magnetic Resonance Imaging (MRI) Hysterosalpingography Versus Radiographic Hysterosalpingography in Female Infertility Completed NCT02108665 Not Applicable
49 Surgical Success After Laparoscopic vs Abdominal Hysterectomy Completed NCT01793584 Not Applicable
50 Electronic Catheter Stethoscope Completed NCT01463462
51 Effect of Salpingectomy During Conservative Hysterectomy Completed NCT01628432 Not Applicable
52 Sonohysterography , 3D Ultrasonography and Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility Completed NCT02399501 Not Applicable
53 The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms Recruiting NCT02495311
54 A Multi-omics Study of Adenomyosis Recruiting NCT03742843
55 Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Recruiting NCT03302468
56 Cooperative Adenomyosis Network Recruiting NCT03230994
57 Dienogest for Treatment of Adenomyotic Uteri Recruiting NCT03890042 Not Applicable Dienogest group;Gestodene-Ethinyl Estradiol
58 Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Recruiting NCT02914704 Not Applicable
59 Paracervical Block in Laparoscopic Hysterectomy Recruiting NCT03792009 Not Applicable 5% bupivacaine;Normal saline
60 Drainage or Not for Laparoscopic Cholecystetomy Recruiting NCT03909360 Not Applicable
61 Acceptability and Tolerance of Hysteroscopy and Hysterosonography in Consultation Recruiting NCT03121560 Not Applicable
62 Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Active, not recruiting NCT02197923
63 High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Enrolling by invitation NCT02954757 Not Applicable
64 Adenomyosis: Genomic Mechanisms and Biological Response Not yet recruiting NCT03428854 LNG-IUS
65 Safety and Efficacy of Actamax™Adhesion Barrier in Women Undergoing Laparoscopic Abdominopelvic Surgery/Myomectomy Not yet recruiting NCT03450421 Not Applicable
66 ICG to Assess Ovarian Perfusion Not yet recruiting NCT03927651 Early Phase 1 ICG
67 The DETECT Study: Discovery and Evaluation of Testing for Endometrial Cancer in Tampons Not yet recruiting NCT03538665
68 Norwegian Adenomyosis Study III: Peristalsis Suspended NCT02197936
69 A Prospective Study of Diagnostic Accuracy of Ultrasound Terminated NCT03120078
70 Functional Brain Imaging and Psychological Testing in Women With Chronic Pelvic Pain Withdrawn NCT02160483 Not Applicable

Search NIH Clinical Center for Adenomyosis

Cochrane evidence based reviews: adenomyosis

Genetic Tests for Adenomyosis

Anatomical Context for Adenomyosis

MalaCards organs/tissues related to Adenomyosis:

42
Uterus, Breast, Pituitary, Ovary, Testes, Endothelial, Cervix

Publications for Adenomyosis

Articles related to Adenomyosis:

(showing 1202, show less)
# Title Authors Year
1
Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids. ( 30382803 )
2019
2
Correlation of LOX‑5 and COX‑2 expression with inflammatory pathology and clinical features of adenomyosis. ( 30387822 )
2019
3
Does presence of adenomyosis affect reproductive outcome in IVF cycles? A retrospective analysis of 973 patients. ( 30446308 )
2019
4
Histological evaluation of the prevalence of adenomyosis, myomas and of their concomitance. ( 30486633 )
2019
5
The Disease Phenotype of Adenomyosis-Affected Women Correlates With Specific Serum Cytokine Profiles. ( 30518300 )
2019
6
Malignant transformation of adenomyosis: literature review and meta-analysis. ( 30519753 )
2019
7
Transmembrane G protein-coupled receptor 30 gene polymorphisms and uterine adenomyosis in Korean women. ( 30626229 )
2019
8
Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and/or adenomyosis. ( 30675965 )
2019
9
What if deep endometriotic nodules and uterine adenomyosis were actually two forms of the same disease? ( 30722943 )
2019
10
In Vivo Adenomyosis Tissue Sampling Using a Transvaginal Ultrasound-guided Core Biopsy Technique for Research Purposes: Safety, Feasibility, and Effectiveness. ( 30738919 )
2019
11
Diffuse massive adenomyosis and infertility. Is it possible to treat this condition? ( 30753160 )
2019
12
Two- and three-dimensional transvaginal ultrasonography for diagnosis of adenomyosis of the inner myometrium. ( 30792048 )
2019
13
Decreased Expression of Cannabinoid Receptors in the Eutopic and Ectopic Endometrium of Patients with Adenomyosis. ( 30800671 )
2019
14
Systematic review and meta-analysis of adverse pregnancy outcomes after uterine adenomyosis. ( 30828808 )
2019
15
Expression of Cannabinoid Receptors in Myometrium and its Correlation With Dysmenorrhea in Adenomyosis. ( 30832539 )
2019
16
Intrauterine cystic adenomyosis: Report of two cases. ( 30863769 )
2019
17
Adenomyosis: genetics of estrogen metabolism. ( 30878995 )
2019
18
Clinical efficacy of adenomyomectomy using "H" type incision combined with Mirena in the treatment of adenomyosis. ( 30882624 )
2019
19
Erratum: The rate of euploid miscarriage is increased in the setting of adenomyosis. ( 30895972 )
2019
20
Recent advances in understanding and managing adenomyosis. ( 30918629 )
2019
21
Adenomyosis:A Clinico-pathological Study. ( 30924123 )
2019
22
Uterine polyps, adenomyosis, leiomyomas, and endometrial receptivity. ( 30929720 )
2019
23
Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis. ( 30994010 )
2019
24
Association between preoperative adenomyosis detection rate during pelvic ultrasonography and the specialty of the reading physician. ( 31004795 )
2019
25
Vaginal Bromocriptine Improves Pain, Menstrual Bleeding and Quality of Life in Women with Adenomyosis; A Pilot study. ( 31025313 )
2019
26
Management of uterine adenomyosis: current trends and uterine artery embolization as a potential alternative to hysterectomy. ( 31030317 )
2019
27
Impact of Coexisting Uterine Adenomyosis on the Survival Outcome of Patients with Endometrial Cancer: A Retrospective Cohort Study ( 31030493 )
2019
28
Uterine artery embolisation in women with symptomatic adenomyosis. ( 31036387 )
2019
29
Incidental Detection of Endometriosis with 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in a Patient with Cervical Intraepithelial Neoplasia and Adenomyosis. ( 31040534 )
2019
30
Elasticity of adenomyosis is increased after GnRHa therapy and is associated with spontaneous pregnancy in infertile patents. ( 31067498 )
2019
31
Effect of pretreatment with a levonorgestrel-releasing intrauterine system on IVF and vitrified-warmed embryo transfer outcomes in women with adenomyosis. ( 31109894 )
2019
32
Sonographic classification and reporting system for diagnosing adenomyosis. ( 29790217 )
2019
33
The Possible Role of Eukaryotic Translation Initiation Factor 3 Subunit e (eIF3e) in the Epithelial-Mesenchymal Transition in Adenomyosis. ( 29871559 )
2019
34
Menstruation-related disseminated intravascular coagulation in an adenomyosis patient: case report and review of the literature. ( 30044152 )
2019
35
Inter-rater agreement in the diagnosis of adenomyosis by 2- and 3-dimensional transvaginal ultrasonography. ( 30182497 )
2019
36
Effects of adenomyosis on obstetric outcomes. ( 30318871 )
2019
37
Risk of preterm birth, low birthweight and small-for-gestational-age infants in pregnancies with adenomyosis: A cohort study of the Japan Environment and Children's Study. ( 30367455 )
2019
38
Coexistence of adenomyosis, adenocarcinoma, endometrial and myometrial lesions in resected uterine specimens. ( 30101029 )
2018
39
Uterine adenomyosis and adenomyoma: the surgical approach. ( 29566853 )
2018
40
RhoA/ROCK/ARHGAP26 signaling in the eutopic and ectopic endometrium is involved in clinical characteristics of adenomyosis. ( 30387365 )
2018
41
Elusive adenomyosis: a plea for an international classification system to allow artificial intelligence approaches to reset our clinical management. ( 30396546 )
2018
42
A sonographic classification of adenomyosis: interobserver reproducibility in the evaluation of type and degree of the myometrial involvement. ( 30396560 )
2018
43
P21-Activated Kinase 1 Overactivates in Eutopic Endometrium of Adenomyosis. ( 30453819 )
2018
44
Catechol-O-methyltransferase 158G/A polymorphism and endometriosis/adenomyosis susceptibility: A meta-analysis in the Chinese population. ( 30539833 )
2018
45
Cerebral infarcts associated with adenomyosis: a rare risk factor for stroke in middle-aged women: a case series. ( 30567506 )
2018
46
Decreased Endometrial IL-10 Impairs Endometrial Receptivity by Downregulating HOXA10 Expression in Women with Adenomyosis. ( 30687738 )
2018
47
Window of Implantation is Significantly Displaced in Patients with Adenomyosis with Previous Implantation Failure as Determined by Endometrial Receptivity Assay. ( 30787520 )
2018
48
Biological differences between focal and diffuse adenomyosis and response to hormonal treatment. ( 30850322 )
2018
49
The rate of euploid miscarriage is increased in the setting of adenomyosis. ( 30895252 )
2018
50
Cerebral Infarcts by Nonbacterial Thrombotic Endocarditis Associated with Adenomyosis: A Case Report. ( 29108806 )
2018
51
Improving Ultrasound Detection of Uterine Adenomyosis Through Computational Texture Analysis. ( 29112637 )
2018
52
Adenomyosis: fertility and obstetric outcome. A comprehensive literature review. ( 29115118 )
2018
53
Re: Changes in anti-müllerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid. ( 29148159 )
2018
54
Author's reply re: Changes in anti-müllerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid. ( 29148166 )
2018
55
Thermal bowel injury after ultrasound-guided high-intensity focused ultrasound treatment of uterine adenomyosis. ( 29154472 )
2018
56
Value of in vitro acoustic radiation force impulse application on uterine adenomyosis. ( 29177930 )
2018
57
Impact of coexistent adenomyosis on outcomes of patients with endometrioid endometrial cancer: a propensity score-matched analysis. ( 29192745 )
2018
58
Experience of Symptoms and Disease Impact in Patients with Adenomyosis. ( 29197944 )
2018
59
Surgery in adenomyosis. ( 29197987 )
2018
60
Influence of adenomyosis on pregnancy and perinatal outcomes in women with endometriosis. ( 29266553 )
2018
61
Positive associations between upregulated levels of stress-induced phosphoprotein 1 and matrix metalloproteinase-9 in endometriosis/adenomyosis. ( 29304094 )
2018
62
Reproductive Outcomes after Fertility-Sparing Surgery for Focal and Diffuse Adenomyosis: A Systematic Review. ( 29305234 )
2018
63
Transvaginal Elastosonography as an Imaging Technique for Diagnosing Adenomyosis. ( 29320956 )
2018
64
A clinical audit on the efficacy and safety of uterine artery embolisation for symptomatic adenomyosis: Results in 117 women. ( 29344938 )
2018
65
The Risk of Preterm Births Among Pregnant Women With Adenomyosis. ( 29363150 )
2018
66
The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor in myoma and adenomyosis. ( 29372159 )
2018
67
Fertility-Sparing Treatment of Adenomyosis in Patients With Infertility: A Systematic Review of Current Options. ( 29402199 )
2018
68
Re: A comparison of the cost-utility of ultrasound-guided high-intensity focused ultrasound and hysterectomy for adenomyosis: a retrospective study: Is the cost-effectiveness of HIFU for adenomyosis and fibroids feasible? ( 29405542 )
2018
69
Re: Pregnancy outcomes in patients with uterine fibroids treated with ultrasound-guided high-intensity focused ultrasound: Is the noninvasive nature of HIFU ablation for uterine fibroids and adenomyosis setting patients up for future operative delivery? ( 29405613 )
2018
70
ILK-induced epithelial-mesenchymal transition promotes the invasive phenotype in adenomyosis. ( 29409901 )
2018
71
Anterior Focal Adenomyosis and Bladder Deep Infiltrating Endometriosis: Is There a Link? ( 29432902 )
2018
72
Combination therapeutic effects of high intensity focused ultrasound and Metformin for the treatment of adenomyosis. ( 29434812 )
2018
73
Operation, hormone therapy and recovery of the patients with severe forms of adenomyosis. ( 29447009 )
2018
74
Effect of pre-treatment with gonadotropin-releasing hormone analogue GnRH-α on high-intensity focussed ultrasound ablation for diffuse adenomyosis: a preliminary study. ( 29447020 )
2018
75
Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial. ( 29496654 )
2018
76
Ultrasound diagnosis of endometriosis and adenomyosis: State of the art. ( 29506961 )
2018
77
Magnetic resonance imaging of degeneration of uterine adenomyosis during pregnancy and post-partum period. ( 29516583 )
2018
78
Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study. ( 29522577 )
2018
79
Introduction: Uterine adenomyosis, another enigmatic disease of our time. ( 29526476 )
2018
80
Drug therapy for adenomyosis: a prospective, nonrandomized, parallel-controlled study. ( 29552942 )
2018
81
News on Adenomyosis. ( 29554861 )
2018
82
Minimally invasive treatment of adenomyosis. ( 29555380 )
2018
83
Pathogenesis of uterine adenomyosis: invagination or metaplasia? ( 29566849 )
2018
84
Symptoms and classification of uterine adenomyosis, including the place of hysteroscopy in diagnosis. ( 29566850 )
2018
85
Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis. ( 29566851 )
2018
86
Role of medical therapy in the management of uterine adenomyosis. ( 29566852 )
2018
87
Association of Endometriosis and Adenomyosis: Vast Literature but Scant Conclusive Data. ( 29581073 )
2018
88
Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas. ( 29626678 )
2018
89
Adenomyosis and urinary system symptoms. ( 29655132 )
2018
90
Associations between a single nucleotide polymorphism of stress-induced phosphoprotein 1 and endometriosis/adenomyosis. ( 29673672 )
2018
91
Clinical Usefulness of the Microbubble Contrast Agent SonoVue in Enhancing the Effects of High-Intensity Focused Ultrasound for the Treatment of Adenomyosis. ( 29689636 )
2018
92
Conservative surgery of diffuse adenomyosis with TOUA: Single surgeon experience of one hundred sixteen cases and report of fertility outcomes. ( 29699636 )
2018
93
The Investigation and Management of Adenomyosis in Women Who Wish to Improve or Preserve Fertility. ( 29736395 )
2018
94
Berberine inhibits growth and inflammatory invasive phenotypes of ectopic stromal cells: Imply the possible treatment of adenomyosis. ( 29752208 )
2018
95
Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small-for-gestational-age child: a systematic review and meta-analysis. ( 29753309 )
2018
96
Effects of pelvic endometriosis and adenomyosis on ciliary beat frequency and muscular contractions in the human fallopian tube. ( 29753325 )
2018
97
Accuracy and Reproducibility of Sonoelastography for the Assessment of Fibroids and Adenomyosis, with Magnetic Resonance Imaging as Reference Standard. ( 29784438 )
2018
98
Conservative surgery of uterine adenomyosis via laparoscopic versus laparotomic approach in a single institution. ( 29845687 )
2018
99
Long-term dienogest administration in patients with symptomatic adenomyosis. ( 29845696 )
2018
100
Adenomyosis and Endometrial Cancer: Literature Review. ( 29874641 )
2018
101
Evaluation of NovaSure® global endometrial ablation in symptomatic adenomyosis: A longitudinal study with a 36 month follow-up. ( 29886317 )
2018
102
Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? ( 29893860 )
2018
103
GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity. ( 29922037 )
2018
104
Endophytic-Type Endometrial Cancer with Adenomyosis Successfully Diagnosed with Hysteroscopic Endometrial Biopsy Using an 8.3-mm Operative Resectoscope: A Case Report. ( 29928209 )
2018
105
Drug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science. ( 29962279 )
2018
106
Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis. ( 29998482 )
2018
107
Adenomyosis and IVF/ICSI treatment: clinical considerations and recommendations. ( 30063420 )
2018
108
Current facts constituting an understanding of the nature of adenomyosis. ( 30085434 )
2018
109
Use of Uterine Characteristics to Improve Fertility-Sparing Diagnosis of Adenomyosis. ( 30087549 )
2018
110
A New Surgical Method of U-Shaped Myometrial Excavation and Modified Suture Approach with Uterus Preservation for Diffuse Adenomyosis. ( 30112362 )
2018
111
Endometrial L-selectin ligand is downregulated in the mid-secretory phase during the menstrual cycle in women with adenomyosis. ( 30122569 )
2018
112
"Recurrent multiple cerebral infarctions related to the progression of adenomyosis: a case report". ( 30129425 )
2018
113
Treatment of Adenomyosis with Subcutaneous Etonogestrel Implants: A Clinical Observational Study in 17 Patients. ( 30171680 )
2018
114
Adenomyosis and Myomata: Risks, Problems, and Complications in Diagnosis and Therapy of Adenomyosis and Myomata. ( 30175136 )
2018
115
Persistence of Symptoms After Total vs Supracervical Hysterectomy in Women with Histopathological Diagnosis of Adenomyosis. ( 30205164 )
2018
116
Adenomyosis: A Sonographic Diagnosis. ( 30207945 )
2018
117
Transvaginal Natural Orifice Transluminal Endoscopic Surgery Hysterectomy in a Woman with Uterine Adenomyosis and Multiple Severe Abdominal Adhesions. ( 30254941 )
2018
118
Efficacy of Hormonal Therapies for Decreasing Uterine Volume in Patients with Adenomyosis. ( 30254953 )
2018
119
Incarceration of early gravid uterus with adenomyosis and myoma: report of two patients managed with uterine reduction. ( 30254999 )
2018
120
The Association of Sonographic Evidence of Adenomyosis with Severe Endometriosis and Gene Expression in Eutopic Endometrium. ( 30273686 )
2018
121
OC01: Transvaginal ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis. ( 30284361 )
2018
122
Cerebral infarction associated with benign mucin-producing adenomyosis: report of two cases. ( 30286732 )
2018
123
Comparison of effectiveness of epidural analgesia and monitored anesthesia care for high-intensity focused ultrasound treatment of adenomyosis. ( 30303419 )
2018
124
High intensity focused ultrasound treatment of adenomyosis: a comparative study. ( 30306813 )
2018
125
Magnetic resonance imaging features influencing high-intensity focused ultrasound ablation of adenomyosis with a nonperfused volume ratio of ≥90% as a measure of clinical treatment success: retrospective multivariate analysis. ( 30307340 )
2018
126
A new era in diagnosing adenomyosis is coming. ( 30316431 )
2018
127
Development of a clinical prediction model for diagnosing adenomyosis. ( 30316443 )
2018
128
Clinical Manifestations of Adenomyosis Patients with or without Coexisting Endometriosis. ( 30334538 )
2018
129
Endometrial receptivity and adenomyosis. ( 30342640 )
2018
130
FAK regulates epithelial‑mesenchymal transition in adenomyosis. ( 30365102 )
2018
131
Predisposing factors for predicting the therapeutic response of adenomyosis after uterine artery embolization: serum CA125 levels and accompanying endometriosis. ( 30373724 )
2018
132
Adenomyosis and adverse perinatal outcomes: increased risk of second trimester miscarriage, preeclampsia, and placental malposition. ( 28110584 )
2018
133
The role of T1 perfusion-based classification in predicting the outcome of magnetic resonance-guided high-intensity focused ultrasound treatment of adenomyosis. ( 28540825 )
2018
134
Conservative Surgery for Adenomyosis and Results: A Systematic Review. ( 28739414 )
2018
135
Hysteroscopic Treatment of a Uterine Cystic Adenomyosis. ( 28751234 )
2018
136
Decreased expression of interleukin-37 in the ectopic and eutopic endometria of patients with adenomyosis. ( 28762845 )
2018
137
Unique Learning System for Uterine Artery Embolization for Symptomatic Myoma and Adenomyosis for Obstetrician-Gynecologists in Cooperation with Interventional Radiologists: Evaluation of UAE From the Point of View of Gynecologists Who Perform UAE. ( 28807810 )
2018
138
Transvaginal Ultrasound for the Diagnosis of Adenomyosis: Systematic Review and Meta-Analysis. ( 28864044 )
2018
139
T2 relaxometry mapping in demonstrating layered uterine architecture: parameter optimization and utility in endometrial carcinoma and adenomyosis: a feasibility study. ( 28936889 )
2018
140
Hysteroscopic Removal of Retained Products of Conception Implanted Over a Focal Area of Adenomyosis: A Case Report. ( 28939480 )
2018
141
The Effect of Adenomyosis in Myometrial Invasion and Overall Survival in Endometrial Cancer. ( 29040186 )
2018
142
The Effects of Dienogest on Macrophage and Natural Killer Cells in Adenomyosis: A Randomized Controlled Study. ( 29043703 )
2018
143
Treatment options and reproductive outcome for adenomyosis-associated infertility. ( 29046066 )
2018
144
Nonbacterial Thrombotic Endocarditis Complicated by Cerebral Infarction in a Patient with Adenomyosis with High Serum CA125 Level; A Case Report. ( 29102541 )
2018
145
[The expression of moesin, p21-activated kinase 4 (PAK 4), matrix metalloproteinases (MMP 2, MMP 9), and CD34 in the eutopic and ectopic endometrium in adenomyosis]. ( 30585588 )
2018
146
Expression Pattern of G-Protein-Coupled Estrogen Receptor in Myometrium of Uteri with and without Adenomyosis. ( 29109960 )
2017
147
Elevated plasma levels of lysophosphatidic acid and aberrant expression of lysophosphatidic acid receptors in adenomyosis. ( 29178922 )
2017
148
Comorbidity of gynecological and non-gynecological diseases with adenomyosis and endometriosis. ( 29184867 )
2017
149
Effects of Jiawei Shaoyao-Gancao Decoction and Its Drug-Containing Serum on Proliferation, Apoptosis, and Ultrastructure of Human Adenomyosis Foci Cells. ( 29234429 )
2017
150
Myomas and Adenomyosis: Impact on Reproductive Outcome. ( 29234680 )
2017
151
Phenotypic characterization of adenomyosis occurring at the inner and outer myometrium. ( 29253010 )
2017
152
Clinical outcomes of infertility treatment for women with adenomyosis in Japan. ( 29259478 )
2017
153
Complications and outcomes of pregnant women with adenomyosis in Japan. ( 29259486 )
2017
154
Immune-inflammatory predictors of the pelvic pain syndrome associated with adenomyosis. ( 29264987 )
2017
155
Berberine inhibits the LPS-induced proliferation and inflammatory response of stromal cells of adenomyosis tissues mediated by the LPS/TLR4 signaling pathway. ( 29285168 )
2017
156
Treatment of cornual pregnancy in a patient with adenomyosis by high-intensity focused ultrasound (HIFU) ablation: A case report. ( 29310371 )
2017
157
From Clinical Symptoms to MR Imaging: Diagnostic Steps in Adenomyosis. ( 29349064 )
2017
158
Serum Osteopontin Levels Are Decreased in Focal Adenomyosis. ( 27678100 )
2017
159
Temporarily Blocking the Uterine Artery to Dig Out a Diffused Adenomyosis Lesion Treated Laparoscopically. ( 27702702 )
2017
160
Endometriotic Pain Is Associated with Adenomyosis but Not with the Compartments Affected by Deep Infiltrating Endometriosis. ( 27710968 )
2017
161
Ultrasound-guided transcervical radiofrequency ablation for symptomatic uterine adenomyosis. ( 27792415 )
2017
162
Adenomyosis and Abnormal Uterine Bleeding (AUB-A)-Pathogenesis, diagnosis, and management. ( 27810281 )
2017
163
Decreased Endometrial Expression of Leukemia Inhibitory Factor Receptor Disrupts the STAT3 Signaling in Adenomyosis During the Implantation Window. ( 27903796 )
2017
164
Immunohistochemical expression pattern of metastasis suppressor KISS-1 protein in adenomyosis lesions and normal endometrium. ( 27940396 )
2017
165
Downregulation of DNA methyltransferase 3 alpha promotes cell proliferation and invasion of ectopic endometrial stromal cells in adenomyosis. ( 27986572 )
2017
166
Safety of ultrasound-guided high-intensity focused ultrasound ablation for diffuse adenomyosis: A retrospective cohort study. ( 28069193 )
2017
167
Myofibroblasts Are Evidence of Chronic Tissue Microtrauma at the Endometrial-Myometrial Junctional Zone in Uteri With Adenomyosis. ( 28093048 )
2017
168
Imaging in Endometriosis and Adenomyosis. ( 28106642 )
2017
169
Percutaneous microwave ablation with artificial ascites for symptomatic uterine adenomyosis: initial experience. ( 28118773 )
2017
170
Current status of high-intensity focused ultrasound for the management of uterine adenomyosis. ( 28145109 )
2017
171
Unusual appearance of adenomyosis on sonohysterography. ( 28164312 )
2017
172
Molecular Characteristics of the Endometrium in Uterine Adenomyosis and Its Biochemical Microenvironment. ( 28183227 )
2017
173
Deep Adenomyosis. ( 28189774 )
2017
174
MRI, US or real-time virtual sonography in the evaluation of adenomyosis? ( 28197875 )
2017
175
High intensity focused ultrasound treatment of adenomyosis: The relationship between the features of magnetic resonance imaging on T2 weighted images and the therapeutic efficacy. ( 28267526 )
2017
176
Transcriptome analysis of endometrial tissues following GnRH agonist treatment in a mouse adenomyosis model. ( 28331289 )
2017
177
Leonurine Attenuates Hyperalgesia in Mice with Induced Adenomyosis. ( 28389633 )
2017
178
Interaction of macrophages and endometrial cells induces epithelial-mesenchymal transition-like processes in adenomyosis. ( 28395325 )
2017
179
Eutopic/ectopic endometrial apoptosis initiated by bilateral uterine artery occlusion: A new therapeutic mechanism for uterus-sparing surgery in adenomyosis. ( 28406930 )
2017
180
High intensity focused ultrasound for the treatment of adenomyosis: selection criteria, efficacy, safety and fertility. ( 28437003 )
2017
181
Endometrial cancer arising in adenomyosis versus endometrial cancer coexisting with adenomyosis: are these two different entities? ( 28444512 )
2017
182
Expression of CXCL12 and its receptor CXCR4 in patients with adenomyosis. ( 28454459 )
2017
183
CA125 modified by PLT and NLR improves the predictive accuracy of adenomyosis-derived pelvic dense adhesion. ( 28489790 )
2017
184
Different macrophages equally induce EMT in endometria of adenomyosis and normal. ( 28495851 )
2017
185
Relationship between the magnetic resonance imaging appearance of adenomyosis and endometriosis phenotypes. ( 28510724 )
2017
186
Uterine Artery Embolization for Symptomatic Adenomyosis: 7-Year Clinical Follow-up Using UFS-Qol Questionnaire. ( 28516272 )
2017
187
Hysteroscopic excision of symptomatic myometrial adenomyosis: feasibility and effectiveness. ( 28544260 )
2017
188
Increased annexin A2 and decreased β-catenin in adenomyosis contribute to adenomyosis-associated dysmenorrhea. ( 28547742 )
2017
189
Endocannabinoids modulate apoptosis in endometriosis and adenomyosis. ( 28549792 )
2017
190
Uterine-Sparing Laparoscopic Pelvic Plexus Ablation, Uterine Artery Occlusion, and Partial Adenomyomectomy for Adenomyosis. ( 28552655 )
2017
191
Two cases of endometrial cancer arising from adenomyosis during aromatase inhibitors therapy after mastectomy. ( 28553743 )
2017
192
Uterine adenomyosis and infertility, review of reproductive outcome after in vitro fertilization and surgery. ( 28556124 )
2017
193
Menorrhagia and Uterine Volume Associated with Lower Urinary Tract Symptoms in Patients with Adenomyosis. ( 28639570 )
2017
194
Laparoscopic Surgery for Focal Adenomyosis. ( 28642638 )
2017
195
New paradigms in the conservative surgical and interventional management of adenomyosis. ( 28665807 )
2017
196
Pathogenesis of adenomyosis: an update on molecular mechanisms. ( 28693952 )
2017
197
Adenomyosis: Back to the future? ( 28721180 )
2017
198
Long-term use of dienogest in the treatment of painful symptoms in adenomyosis. ( 28737239 )
2017
199
A Rare Case of Intramural Müllerian Adenosarcoma Arising from Adenomyosis of the Uterus. ( 28741605 )
2017
200
Rhein ameliorates adenomyosis by inhibiting NF-κB and β-Catenin signaling pathway. ( 28763746 )
2017
201
Concomitant use of transvaginal sonography and Doppler indices improve diagnosis of adenomyosis. ( 28766365 )
2017
202
The Expression of Toll-like receptors in eutopic and ectopic endometrium and its implication in the inflammatory pathogenesis of adenomyosis. ( 28779087 )
2017
203
The impact of adenomyosis on the outcome of IVF-embryo transfer. ( 28802706 )
2017
204
Abnormal expression of Nrf2 may play an important role in the pathogenesis and development of adenomyosis. ( 28817677 )
2017
205
Quercetin alleviates generalized hyperalgesia in mice with induced adenomyosis. ( 28849202 )
2017
206
The Role of Hysteroscopy in the Diagnosis and Treatment of Adenomyosis. ( 28852646 )
2017
207
Immunohistochemical Parameters of Musashi-1 in Nodular and Diffuse Adenomyosis. ( 28853072 )
2017
208
The effect of exercise on high-intensity focused ultrasound treatment efficacy in uterine fibroids and adenomyosis: a retrospective study. ( 28856860 )
2017
209
Gonadotrophin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study. ( 28856862 )
2017
210
A comparison of the cost-utility of ultrasound-guided high-intensity focused ultrasound and hysterectomy for adenomyosis: a retrospective study. ( 28856866 )
2017
211
Changes in anti-müllerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid. ( 28856867 )
2017
212
Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis. ( 28865548 )
2017
213
Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. ( 28911934 )
2017
214
Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. ( 28927080 )
2017
215
MRI for adenomyosis: a pictorial review. ( 28980163 )
2017
216
Uterine Artery Embolization for the Treatment of Adenomyosis: A Systematic Review and Meta-Analysis. ( 29032946 )
2017
217
Serous carcinoma arising from adenomyosis. ( 29037565 )
2017
218
MicroRNA-17 downregulates expression of the PTEN gene to promote the occurrence and development of adenomyosis. ( 29042983 )
2017
219
Malignant changes in adenomyosis in patients with endometrial adenocarcinoma: A case series. ( 29069006 )
2017
220
Endometrioid adenocarcinoma originating simultaneously from endometrium, sites of adenomyosis and ovarian endometriosis: A case report and review of our cancer database. ( 29096350 )
2017
221
Sonographic Signs of Adenomyosis Are Prevalent in Women Undergoing Surgery for Endometriosis and May Suggest a Higher Risk of Infertility. ( 29098162 )
2017
222
Low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for successful long-term management of adenomyosis associated with cerebral venous and sinus thrombosis from low-dose oral contraceptive use. ( 29714885 )
2017
223
The benefit of adenomyomectomy on fertility outcomes in women with rectovaginal endometriosis with coexisting adenomyosis. ( 30254864 )
2017
224
Expression of Inflammatory and Neurogenic Mediators in Adenomyosis. ( 27440813 )
2017
225
Prolactin role in the bovine uterus during adenomyosis. ( 27591979 )
2017
226
[Discussion on the acupuncture and moxibustion thoughts of diagnosis and treatment for secondary dysmenorrhea of adenomyosis on the basis of disease location and pathogenesis]. ( 29354982 )
2017
227
Pyoadenomyosis: A Rare Complication of Adenomyosis. ( 27670700 )
2016
228
Pregnancy rate in women with adenomyosis undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing hormone agonist treatment. ( 27689040 )
2016
229
Live birth in a woman with recurrent implantation failure and adenomyosis following transfer of refrozen-warmed embryos. ( 27689042 )
2016
230
Anti-platelet therapy holds promises in treating adenomyosis: experimental evidence. ( 27724926 )
2016
231
Treatment strategies for pelvic pain associated with adenomyosis. ( 27759444 )
2016
232
Proangiogenic features in chronic pelvic pain caused by adenomyosis. ( 27759451 )
2016
233
Estradiol Reduces Connexin43 Gap Junctions in the Uterus during Adenomyosis in Cows. ( 27760016 )
2016
234
Down-regulation of tumor suppressor PDCD4 expression in endometrium of adenomyosis patients. ( 27765271 )
2016
235
Outcomes in Adenomyosis Treated with Uterine Artery Embolization Are Associated with Lesion Vascularity: A Long-Term Follow-Up Study of 252 Cases. ( 27806072 )
2016
236
Rare Case of Leiomyoma and Adenomyosis in Mayer-Rokitansky-Kuster-Hauser Syndrome. ( 27843659 )
2016
237
Value of ultrasound shear wave elastography in the diagnosis of adenomyosis. ( 27847535 )
2016
238
Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis. ( 27865118 )
2016
239
Authors' Response: Expression of CD56 in patients with adenomyosis and its correlation with dysmenorrhea. ( 27889198 )
2016
240
UTERINE ADENOMYOSIS AND AN ENDOMETRIAL POLYP IN A ROCK HYRAX (PROCAVIA CAPENSIS). ( 28080921 )
2016
241
Urinary Obstruction of Transplanted Kidney Caused by Uterine Adenomyosis and 2-Year Posthysterectomy Psoas Abscess in Conjunction with Transplanted Kidney. ( 28097036 )
2016
242
Heavy menstrual bleeding and dysmenorrhea are improved by Magnetic Resonance Guided Focused Ultrasound Surgery (MRgFUS) of adenomyosis. ( 28620535 )
2016
243
Cytokine Profiling in the Eutopic Endometrium of Adenomyosis During the Implantation Window After Ovarian Stimulation. ( 26239388 )